x
Ariana Pharma
[contact-form-7 404 "Not Found"]

Ariana Pharma
  • Contact Us
  • Home
  • About Us
  • Our Business
  • Our Technology
  • Real World Data
  • News & more
    • In The News
    • Case study
    • Publications
      • Publications & Conferences
      • Whitepaper & blog
  • Careers
Logo

Contact Info

  • 58-60 Avenue de la Grande Armée, 75017, Paris, France
  • +33 1 44 37 17 00
  • info@arianapharma.com

Clinical Trials on Alzheimer’s Disease Conference (CTAD) 2022

CY6463 administration in healthy participants was associated with improvements in Alzheimer’s diseaserelevant biomarkers based on a systematic analysis of multiple Phase 1 clinical trials using KEM® eXplainable AI.

Martin Kindermans 1, Hichem Chakroun 1, Jennifer Chickering 2, Chad Glasser 2, Pablo Iriso 1, Frederic Parmentier 1, Todd Milne 2, Phebe Wilson 2, Mohammad Afshar 1 1Ariana Pharma – Paris (France), 2Cyclerion – Cambridge (United States)
Abstract
Poster

Ariana Pharmaceuticals, The AI DRUG Development Company

  • Paris, FRANCE / Cambridge, MA, USA
  • Call Us: +33 144 37 17 00
  • info@arianapharma.com

Menu

  • About Us
  • Our business
  • Technology
  • In The News
  • Contact Us

Subscribe

Keep in touch and subscribe to our latest news

    Ariana Pharma © 2024 All Rights Reserved